Effect of metformin on cardiovascular outcomes: a systematic review and meta-analysis of observational studies and RCTs
Abstract
BackgroundMetformin is an oral medication most commonly prescribed to lower blood glucose levels. However, previous systematic reviews have cast doubt on its effectiveness in reducing the risk of cardiovascular disease (CVD), the costliest side effect of type 2 diabetes mellitus (T2DM). ObjectiveThis study aimed to combine data from observational studies and randomised controlled trials to determine the impact of metformin on cardiovascular outcomes in diabetic and non-diabetic population. MethodsOn February 24, 2023, a thorough article search was performed in PubMed, EBSCO, Scopus, Web of Science, and ProQuest using keywords and synonyms of Metformin and CVD, coupled with specific terms for different CVDs. Study quality was evaluated using the Cochrane risk of bias tool and Newcastle–Ottawa Scale. Statistical analysis of the data was conducted using R software. PROSPERO registration: CRD42023404151.ResultsA total of 40,087 studies were found through a literature search, of which 22 studies were identified as eligible, involving 612,823 participants, for the meta-analysis. The overall pooled effect estimate for CVD outcome with metformin treatment was found to be a Risk Ratio (RR) of 0.88 (95% CI:0.76-1.03). The pooled effect estimate indicated a significant reduction in CVD-related mortality with metformin treatment, with an RR of 0.75 (95% CI: 0.60-0.93).ConclusionsThis study provides evidence that metformin treatment may not have a significant effect on composite CVD…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 612,823 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.